Efficacy of phase 1 trials in malignant pleural mesothelioma: Description of a series of patients at a single institutionRAPHAEL, J; LE TEUFF, G; HOLLEBECQUE, A et al.Lung cancer. 2014, Vol 85, Num 2, pp 251-257, issn 0169-5002, 7 p.Article

A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphomaHOLLEBECQUE, A; DEUTSCH, E; VARGA, A et al.Investigational new drugs. 2013, Vol 31, Num 6, pp 1530-1538, issn 0167-6997, 9 p.Article

Low skeletal muscle is associated with toxicity in patients included in phase I trialsCOUSIN, Sophie; HOLLEBECQUE, A; KOSCIELNY, S et al.Investigational new drugs. 2014, Vol 32, Num 2, pp 382-387, issn 0167-6997, 6 p.Article

Chimiothérapie des métastases d'origine colorectale jamais résécables: stratégie multiligne, thérapies ciblées = Chemotherapy for Previously Unresectable Colorectal Metastases: Multi-line Strategies and Targeted TherapiesBOIGE, V; MALKA, D; FERTE, C et al.Oncologie (Paris). 2014, Vol 16, Num 11-12, pp 579-586, issn 1292-3818, 8 p.Article

Bevacizumab-induced laryngeal necrosisHARTL, D. M; BAHLEDA, R; HOLLEBECQUE, A et al.Annals of oncology. 2012, Vol 23, Num 1, pp 276-278, issn 0923-7534, 3 p.Article

Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh scoreHOLLEBECQUE, A; CATTAN, S; HEBBAR, M et al.Alimentary pharmacology & therapeutics. 2011, Vol 34, Num 10, pp 1193-1201, issn 0269-2813, 9 p.Article

Natural history and therapeutic management of recurrent hepatocellular carcinoma after liver transplantationHOLLEBECQUE, A; DECAENS, T; BOLESLAWSKI, E et al.Gastroentérologie clinique et biologique. 2009, Vol 33, Num 5, pp 361-369, issn 0399-8320, 9 p.Article